Pamela Bradt, ICER CSO

ICER crit­i­cizes cost of 8 tar­get­ed im­mune mod­u­la­tors for UC, rec­om­mend­ing some deep dis­counts

While 8 tar­get­ed im­mune mod­u­la­tors (TIMs) on the mar­ket for ul­cer­a­tive col­i­tis have proved ben­e­fi­cial to pa­tients, non­prof­it cost-ef­fec­tive­ness watch­dog ICER called the drugs un­rea­son­ably …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.